30 November 2017
Professor John Mattick AO FAA FAHMS FTSE, the Executive Director of the Garvan Institute of Medical Research, is now a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE).
Prof Mattick was formally welcomed as a new ATSE Fellow (FTSE) on Friday, November 24, at an ATSE New Fellows Seminar at Sofitel Sydney Wentworth. He was one of 25 new Fellows to be elected in 2017.
In the media release announcing the new Fellows, the ATSE said:
“Professor Mattick developed one of the first commercial recombinant DNA-based vaccines in the world. He changed our understanding of the human genome, showing that it specifies an RNA (ribonucleic acid) regulatory system that directs development. He established the Institute for Molecular Bioscience and the Australian Genome Research Facility, and was instrumental in the development of the Queensland Smart State policy, which transformed the research base of that state. He established an international human genome sequencing centre at the Garvan Institute and one of the first clinically accredited genome analysis enterprises in the world.”
Prof Mattick joins Garvan’s Professor Antony Basten AO FAA FTSE as an ATSE Fellow. Prof Basten was elected as a Fellow in 1981.
The ATSE is an independent body of over 800 Australian scientists and engineers committed to enhancing Australia’s prosperity through technological innovation. The new ATSE Fellows for 2017 include academics, business leaders, commercial innovators and public sector figures from a wide range of disciplines including renewable energy, internet technology, vaccine development, robotic vision, geophysics, biotechnology, science communication and biomedical research.
Read the full list of 2017 ATSE Fellows.